6 results match your criteria: "Feng-yue Institute of Orthopaedics & Traumatology[Affiliation]"
Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors.
Glob Med Genet
December 2024
Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, People's Republic of China.
Article Synopsis
- FGFR is a vital receptor involved in growth and tissue repair, but its gene mutations can lead to cancer by disrupting essential processes.
- Small molecule drugs and antibodies targeting FGFR mutations, like erdafitinib and pemigatinib, have shown clinical efficacy in treating certain cancer types.
- Effective screening methods for FGFR variants are essential for utilizing FGFR inhibitors in treatment, and a consensus has been developed to standardize diagnosis and treatment processes.
Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations.
Innovation (Camb)
November 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing 100142, P.R. China.
Article Synopsis
- * BRAF mutations are common in various cancers, and targeted therapies, especially BRAF inhibitors like dabrafenib and trametinib, are developed for treating solid tumors with these mutations.
- * An expert consensus has been established to improve the diagnosis and treatment of solid tumors with BRAF mutations, focusing on summarizing their clinical features, recommending genetic testing methods, and creating a systematic approach for patient care.
Expert Consensus on the Diagnosis and Treatment of Gene Fusion Solid Tumors.
Glob Med Genet
January 2024
Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, People's Republic of China.
Article Synopsis
- Fusion genes from the epidermal growth factor (EGF) receptor family are significant players in cancer development, especially in lung cancer, where gene fusion incidence is 0.19 to 0.27%.
- Common partners for these fusions are CD74 and SLC3A2, and detection methods include RNA-based next-generation sequencing and pERBB3 immunohistochemistry for quick screening.
- Currently, there are no approved specific drugs for these fusions, but treatment options like pan-ERBB inhibitors and monoclonal antibodies are being explored, with clinical trials aiming to improve outcomes for patients with solid tumors containing these gene fusions.
Preparation, biological characterization and preliminary human imaging studies of Ga-DOTA-IBA.
Front Oncol
December 2022
Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Purpose: In this study, DOTA-IBA was radiolabeled with Ga and we determined the optimum labelling conditions and assessed the biological properties of Ga-DOTA-IBA. We investigated the biodistribution of Ga-DOTA-IBA in normal animals and undertook PET/CT imaging in humans. Finally, we explored the feasibility Ga-DOTA-IBA as a bone imaging agent and demonstrated its potential for the therapeutic release of Lu/Ac-DOTA-IBA.
View Article and Find Full Text PDFEffectiveness of Chinese massage therapy (Tui Na) for chronic low back pain: study protocol for a randomized controlled trial.
Trials
October 2014
Chengdu University of Traditional Chinese Medicine, No,37, Shierqiao Road, Jinniu District, Chengdu, Sichuan 610072, China.
Article Synopsis
- - The study aims to compare the effectiveness of tuina massage therapy and conventional pain relief (ibuprofen) for treating chronic low back pain (CLBP), which affects many people worldwide.
- - It involves 150 CLBP patients randomly assigned to receive either tuina massage (20 minutes a session, over 4 weeks) or regular ibuprofen treatment, with outcomes measured using various pain and function assessments.
- - This rigorously designed trial seeks to provide high-quality data on tuina therapy's effectiveness for CLBP, contributing to better clinical practices and future research in massage therapy.
[Study on effect of suifukang in regulating the change of free radical after hemitransected spinal cord injury].
Zhongguo Zhong Xi Yi Jie He Za Zhi
November 2004
Feng-yue Institute of Orthopaedics & Traumatology, China Academy of TCM, Beijing (100700).
Objective: To explore the regulatory effect of Suifukang (SFK), a compound Chinese patent drug on the change of free radical in tissue of spinal cord and blood caused by experimental spinal injury.
Methods: Seventy male adult SD rats were randomly divided into 4 groups, the SFK group (n = 20), the hormone group (n = 20), the control group (n = 20) and the normal group (n = 10). Rats in the former three groups were made into the right hemitransected spinal cord (T12) injury.